Epidermal Malignant Tumors: Pathogenesis, Influence of UV Light and Apoptosis by Larisa Prpić Massari et al.
Coll. Antropol. 31 (2007) Suppl. 1: 83–85
Professional paper
Epidermal Malignant Tumors: Pathogenesis,
Influence of UV Light and Apoptosis
Larisa Prpi} Massari, Marija Ka{telan and Franjo Gruber
Department of Dermatovenerology, Rijeka University Hospital, Rijeka, Croatia
A B S T R A C T
Basal cell carcinoma and squamous cell carcinoma, collectively termed non-melanoma skin cancers are the most
common malignant tumors in humans. Basal cell carcinoma grows slowly and metastatic spread is very rare. Squamous
cell carcinoma is characterized by infiltrative, destructive growth and metastasis. Long-term exposure of skin to UV light
has a great impact on development of these epidermal malignancies. UV light induces cascade of events like well known
DNA damage of keratinocytes as well as still completely undetermined influence on apoptotic process through expression
of proapoptotic and antiapoptotic molecules. The major role in development of skin cancer is given to proapoptotic p53
molecule or tumor suppressor gene which mutation due to UV exposure leads to resistance of DNA-damaged cell to
apoptosis. Other proapoptotic molecules such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) are strongly expressed in basal cell carcinoma and squamous cell carcinoma that could be explained by
the ability of tumor to escape the attack of immune system.
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Introduction
Epidermal malignant tumors are a group of skin can-
cer arising from epidermal cells. It includes mainly basal
cell carcinoma (BCC) and squamous cell carcinoma (SCC),
namely together non-melanoma skin cancer (NMSC)1,2.
NMSC are the most frequent malignant tumors in whi-
tes and its incidence is increasing worldwide1,2.
Basal cell carcinoma accounts for approximately 75%
of all the skin tumors3. Although in the past men were
more prone to this type of skin cancer, the sexual differ-
ence became less pronounced recently. It could be ex-
plained by a novel changes in women lifestyle, especially
in their endeavor to achieve a »beautiful year-around
tan» due to a sun exposure as well as frequent visiting of
skin tanning studios3,4. The raised incidence of skin tu-
mors in both sex is also due to a depletion of the ozone
layer and its inability to filter out the carcinogenic rays
of ultraviolet light (UVB)3,4. BCC grows slowly and meta-
static spread is very rare (around 0.05%)4,5.
Squamous cell carcinoma accounts for 10–20% of all
skin malignancies and is the second most common skin
cancer after BCC4,6. It affects most commonly elderly
white men after the age of 404,6. As well as BCC it is most
consistently related to ultraviolet radiation4,6. Therefore,
outdoors occupation, less protective clothing and ozone
layer depletion contributes mainly to this raising inci-
dence4,6. Contrary to BCC, which very rarely metasta-
size, lymphogenic spread of SCC is very often and this
malignancy is a major cause of death among non-mela-
noma skin cancers (NMSC)4,6.
Etiopathogenesis of Epidermal
Malignant Tumors
The etiology of non-melanoma skin tumors can be ex-
plained as sincarcinogenic effect of different factors such
as irradiation, chemical carcinogens, genetic factors, on-
cogenic viruses and immunosuppression6.
The most common factor involved in the pathogenesis
of these types of skin tumors is ultraviolet light, due to a
sun exposure or use of other UV light sources such as
skin tanning studios or PUVA therapy8. Fair-skinned in-
dividuals (skin type I) who burn easily and do not tan
well are more prone to development of skin tumors in
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comparison to darkly pigmented persons8. Cumulative
lifetime UV exposure and intermittent intense sun expo-
sure early in life leading to sunburn both contribute to
development of skin cancer8. However, 20% of BCCs oc-
curred on non sun exposed skin and therefore the influ-
ence of other etiology factors could be of great impor-
tance as well8.
Ionizing radiation as well as heat could also be a cause
of skin cancer development4,7. Chronic ingestion of arsen
(in groundwater or as a therapy) as well as industrial ex-
posure are also important risk factors. Other carcinogens
include petroleum products, hydrocarbons such as soot,
pitch, tar, shale and mineral oil and tobacco4,7.
Genetic factors are also involved in development of
BCC9,10. Two well known tumor suppressor genes, p53
gene and the patched gene (ptch) are the major targets of
UV light for BCC induction10,11. The p53 is a tumor sup-
pressor gene involved in cell cycle regulation10,11. Muta-
tion in p53 gene, due mainly to a UV light, arrests a cell
growth at G1 phase of the cell cycle, thus preventing a
death of UV damaged cells and subsequently allowing a
cell proliferation and formation of skin cancer10,11. Muta-
tions in the single gene p53 are present in 40–60% of all
skin cancers10,11. The patch gene (ptch) is mainly related
to nevoid basal cell carcinoma syndrome or Gorlin-Goltz
syndrome, an autosomal dominant disorder character-
ized by the development of multiple BCCs at an early
age, medulloblastomas, meningeomas and skeletal ab-
normalities11,12. The patch gene is located on chromo-
some 9q22.311,12. Its allelic loss or inactivation, which oc-
curs in patients with Gorlin-Goltz syndrome, is associa-
ted with an abnormal transcription of patch protein11,12.
This protein is a cell membrane receptor for the Hedge-
hog protein family, responsible for transcriptions of other
proteins important for cell proliferation and function11,12.
Some studies show that this gene also play a role in the
pathogenesis of sporadic BCC11,12.
Some oncogenic viruses especially human papilloma-
virus (HPV) types 6, 11, 16 and 18 has been identified in
a variety of genital, anal and oral SCCs, so their impact
in development of this particular skin malignancy is of a
great importance4. It is believed that genetic parts of
HPV viruses E6 and E7 may inhibit p53 gene function
and therefore allow replication of malignant clone13.
Immunosupressed patients have a greater risk for de-
velopment of skin cancers especially SCC6,7. Solid organ
transplant recipients are especially susceptible for non-
melanoma skin tumors and half of them have multiple
tumors on presentation6,7. Risk for SCC in these patients
is connected to duration and intensity of immunosup-
pression6,7.
Within UV spectrum, absorption of UVB by deoxyri-
bonucleic acid (DNA) within epidermal keratinocytes in-
duces a DNA mutation of pyrimidine dimmers, especially
of tumor suppressor gene or oncogenes6,7. This error is
than replicated and transcripted6,7. Although UVB is
more potent in producing genetic mutation than UVA
and is considered as tumor initiator, molecular studies
show that UVA act as tumor promoter to help expand ini-
tiated tumor cells through modulation of protein kinase
C, a signal transduction molecule6,7. UVA also causes
immunosuppression through secretion of interleukin-10
and subsequent activation of suppressor T-cells6,7.
Chronic skin wound, caused by trauma, ionizing radi-
ation, thermal exposure or chronic skin diseases such as
hidradenitis suppurativa and dystrophic epidermolysis
bullosa may predispose to squamous cell carcinoma de-
velopment that is even more aggressive than other SCCs,
causing a metastasis rate of 38%6,7. The cause of develop-
ment of this type of SCC is not yet completely under-
stood6,7.
The Role of Apoptosis in Development
of Epidermal Malignant Tumors
Apoptosis is a physiological process of programmed
cell death responsible for the homeostasis of a variety of
physiological systems in the body, including skin14. Apo-
ptosis is morphologically characterized by cell shrinkage,
nuclear condensation, cellular fragmentation and finally
phagocytosis by neighboring cells15. In skin, cell death by
apoptosis is an unique way of regulating keratinocyte
proliferation, differentiation and epidermal growth as
well16,17. Balance between cell death and cell prolifera-
tion maintains homeostasis of epidermal compartment18.
The process by which keratinocytes undergo apo-
ptosis is a multistep program that includes several mech-
anisms. Briefly, the »extrinsic» apoptotic pathway is me-
diated by binding of Fas ligand (FasL) or TNF to specific
death receptors thus leading to the activation of different
caspases in an ordered sequence19,20. The »intrinsic»
pathway involves mitochondrial release of multiple pro-
apoptotic factors that ends in final activation of the
caspase-321. Both, apoptosis induced through death re-
ceptors and mitochondria, ends in the activation of the
effector caspase-3, responsible for the cleavage of a vari-
ety of intracellular substrates and for the activation of
caspase-activated deoxyribonuclease that initiates DNA
cleavage22. Finally, the process ends in the formation of
apoptotic bodies and its phagocytosis by neighbouring
macrophages and dendritic cells22. The process of apopto-
sis is controlled by proteins of the Bcl-2 family, i.e. sev-
eral proapoptotic (Bax, Bak, Bad, p53) and antiapoptotic
(Bcl-2, BclxL) proteins
21.
The major feature of non-melanoma skin cancer is
their resistance to apoptosis23. In UV unexposed skin,
FasL and tumor necrosis factor-related apoptosis-induc-
ing ligand (TRAIL) are mainly expressed at basal kera-
tinocytes and less in the upper layers of epidermis, while
TRAIL-R1 and R2 dominate in the upper layer of epi-
dermis24. Upon the UV light exposure FasL, TRAIL and
TRAIL-Rs are downregulated transiently. Consequently,
apoptotic cells are found throughout the epidermis.
When BCC or SCC has developed, the expression of Fas
and TRAIL are strongly upregulated in both tumors, as
well as the expression of several apoptosis inhibitors like
bcl-2 and FLIP24.
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Tumor suppressor p53 gene is included in repairment
of UV-induced DNA damage, therefore p53 gene is con-
sidered as »guardian of the genome«25. If repairment of
DNA is not possible, DNA damaged keratinocytes are
eliminated by programmed cell death or apoptosis, under
the control of p53 gene25.
However, p53 gene could be itself a direct target of UV
radiation. Mutation of this gene can lead to uncontrolled
keratinocyte proliferation and disability to undergo apo-
ptosis. Mutation in the p53 gene are detected in about
56% of BCC and in >90% of SCC26.
In UV non-exposed skin the expression of FasL pre-
vents the influx of inflammatory cells from dermis into
epidermis and also eliminates DNA-damaged cells that
have the potential to transform27. Upon UV exposure,
the expression of FasL is downregulated and mutated
cells could not be eliminated by apoptosis. However, after
a development of skin tumor, upregulation of FasL pro-
tects the tumor from immune-mediated damage provid-
ing its immune escape and further expansion28. More-
over, upregulation of FasL and TRAIL in BCC and SCC
protects the tumor from T cell attack, while at the same
time lack of death receptors (TRAIL R1, R2 and Fas) pre-
vent tumor cell death29. So, it seems that apoptosis plays
an important role in the development and expansion of
NMSC. Therefore, future challenges include the clinical
implications of these data directed toward development
of new apoptosis-based therapeutics in BCC/SCC treat-
ment.
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EPIDERMALNI MALIGNI TUMORI: PATOGENEZA, UTJECAJ UV ZRA^ENJA I APOPTOZA
S A @ E T A K
Bazocelularni karcinom i spinocelularni karcinom, skupno nazvani nemelanomski ko`ni tumori, su naj~e{}i maligni
tumori u ljudi. Bazocelularni karcinom sporo raste i metastazira vrlo rijetko. Spinocelularni karcinom je karakteriziran
infiltrativnim, destruktivnim rastom i metastazama. Dugotrajno izlaganje ko`e ultraljubi~astom zra~enju zna~ajno
utje~e na nastanak ovih epidermalnih ko`nih novotvorina. Ultraljubi~asto zra~enje poti~e slijed doga|aja, kao {to su
dobro poznato o{te}enje DNA keratinocita, kao i jo{ uvijek nedovoljno rasvijetljen proces programirane stani~ne smrti,
odnosno apoptoze regulacijom ispoljavanja proapoptoti~kih i antiapoptoti~kih molekula. Glavna ulogu u nastanku ko`-
nih tumora pridaje se proapoptoti~koj p53 molekuli ili tumor supresor genu ~ija mutacija uzrokovana izlaganjem ultra-
ljubi~astom zra~enju vodi do otpornosti stanice s o{te}enom DNA na apoptozu. Ostale proapoptoti~ke molekule kao na
primjer FasL i TRAIL su tako|er sna`no ispoljene u bazocelularnom i spinocelularnom ko`nom karcinomu, {to mo`e
objasniti sposobnost tumorskih stanica da se obrane od napada imunog sustava.
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